Abstract

Background: The United States (US) has re-instituted smallpox vaccinations to prepare for an intentional release of the smallpox virus into the civilian population. In an outbreak, people of all ages will be vaccinated. To prepare for the impact of large-scale ring and mass vaccinations, we conducted a systematic review of the complication and mortality risks of smallpox vaccination. We summarized these risks for post-vaccinial encephalitis, vaccinia necrosum (progressive vaccinia), eczema vaccinatum, generalized vaccinia, and accidental infection (inadvertant autoinoculation).

Methods: Using a MEDLINE search strategy, we identified 348 articles, of which seven studies met our inclusion criteria (the number of primary vaccinations and re-vaccinations were reported, sufficient data were provided to calculate complication or case-fatality risks, and comparable case definitions were used). For each complication, we estimated of the complication, death, and case-fatality risks.

Results: The life-threatening complications of post-vaccinial encephalitis and vaccinia necrosum were at least 3 and 1 per million primary vaccinations, respectively. Twenty-nine percent of vaccinees with post-vaccinial encephalitis died and 15% with vaccinia necrosum died. There were no deaths among vaccinees that developed eczema vaccinatum; however, 2.3% of non-vaccinated contacts with eczema vaccinatum died. Among re-vaccinees, the risk of post-vaccinial encephalitis was reduced 26-fold, the risk of generalized vaccinia was reduced 29-fold, and the risk of eczema vaccinatum was reduced 12-fold. However, the risk reductions of accidental infection and vaccinia necrosum were modest (3.8 and 1.5 fold respectively).
mail, the US has taken several steps to mitigate a possible intentional release of variola major (smallpox) virus [3–6], including re-instituting a national smallpox vaccination program [7]. For Phase 1 of this program, the Advisory Committee on Immunization Practices (ACIP) recommended voluntary vaccination of 500,000 members of public health response and hospital health care teams [8]. In Phase 2, up to 10 million first responders such as police, fire, paramedics, and other health care staff would be offered voluntary smallpox vaccination.

However, the implementation the smallpox vaccination program is not without controversy [9]. Vaccinating individuals against smallpox infection, even voluntarily, means exposing vaccinees and their contacts to the risks of serious adverse reactions without the clear benefit of protection against an infection which does not exist and may never exist again. Volunteers must balance their individual risks and benefits of smallpox vaccination. The individual risks and benefits from being vaccinated before an intentional release depends on the probability of an adverse vaccine reaction, the probability that smallpox virus will be released, and the probability that an individual would be directly exposed to a release or an unrecognized case of smallpox [10]. Once an outbreak occurs, ring and mass vaccination would result in a large number of primary vaccinees of all ages, including some with underlying or unrecognized risks for vaccine adverse reactions. In this scenario, we would expect to see an increased number and risk of vaccine complications. Estimation of the vaccine complication risks by age, including their precision and estimation biases, are necessary to formulate policies and inform individual choice regarding the risks and benefits of pre-outbreak smallpox vaccination, and to estimate the burden of vaccine complications from ring and mass vaccination during an smallpox outbreak in the general population.

Recent publications [11–16] have summarized or cited the complication risks associated with receiving smallpox vaccination; however, to our knowledge, no systematic review of this older literature has been conducted. The purpose of this systematic review is to review and summarize the age-specific complication and case fatality risks of post-vaccinial encephalitis, vaccinia necrosum (progressive vaccinia), eczema vaccinatum, generalized vaccinia, and accidental infection (inadvertant autoinoculation) from smallpox vaccinations conducted in the US. We restricted our review to US studies because the New York City Board of Health vaccinia strain, which was the only strain used in the US, is the strain in current use by the the national vaccination program (and will be in the future) [11].

Methods

Searching

Two reviewers (T.J.A., S.U.) conducted the literature searches, selection of studies, and data extraction. To identify potential studies we searched MEDLINE which covered 1965 through November 2002. We entered the following search string: ((Smallpox Vaccine/*adverse effects [MeSH terms] AND "English" [Language]) OR ((Vaccination/*adverse effects [MeSH terms] AND "vaccinia" [MeSH terms]) AND "English" [Language])). From this search result, potentially relevant studies on smallpox vaccine complications were identified, screened, and retrieved. The reference lists in all retrieved articles, including reviews, were evaluated to identify, screen, and retrieve additional articles not identified in the MEDLINE search. Selected primary authors were contacted to identify additional studies we may have missed [17,18]. Based on this consultation and our inclusion criteria (described below) we did not pursue articles published before 1965 or from additional US databases.

Selection criteria

All US studies of smallpox vaccine complications were included for further review. Articles were screened further based on the following criteria: (1) the number of persons vaccinated and whether the vaccine complications were reported by vaccination status; that is, whether it was a primary vaccination or a re-vaccination, (2) sufficient data were provided to calculate complication or case-fatality risks, and (3) one or more vaccination complications were consistent with case definitions as defined by Neff and colleagues [19]. Prior to this publication there were no consistent case definitions of smallpox vaccine complications. The following summarizes the Neff criteria:

- Encephalitis: post-vaccinial central nervous system involvement, including separately or in combination, the following symptoms: meningeal signs, ataxia, muscular weakness, paralysis, lethargy, coma or convulsions,
- Vaccinia necrosum (progressive vaccinia): spreading necrosis at the site of the vaccination, with or without metastatic necrotic lesions occurring elsewhere on the body,
- Eczema vaccinatum: generalized spread of vaccinal lesions or local implantation of vaccinia in a person who has eczema or a past history of eczema,
- Generalized vaccinia: generalized vaccinal lesions, with no eczema or other pre-existing lesion,
- Accidental infection: vaccinal lesions resulting from accidental autoinoculation of vaccinia virus in the eye or
mouth or on other parts of the body, with no eczema or other pre-existing skin lesions.

Validity assessment
For this review we did not develop a quality score. Instead, we collected relevant information that might bias the complication and case fatality risk estimates from each article. This included information on the study location, whether potential vaccinees were screened (e.g., history of eczema/atopic dermatitis), reporting source of vaccine complications and deaths (numerators), and source of numbers of persons vaccinated (denominators). This information was summarized to help the reader interpret the findings.

Data abstraction
Data from each article were abstracted separately by the two primary reviewers. For quality control, two additional staff independently abstracted the data, and any disagreements were resolved by the primary reviewers.

Study characteristics
The selected studies were published in English. They had the type and number of vaccine complications, and an estimate of the number of persons vaccinated. The type and number of complications came from several sources which are summarized in Table 1. The number of persons vaccinated were either known as in the US cohort studies [20,21], or were estimated using data from US national or state immunization surveys [19,22–25].

Quantitative data synthesis
Data in all the studies, except the Ratner study, were stratified by vaccination status and by the following age groups (age <1 year, ages 1 to 4 years, ages 5 to 19 years, ages 20+ years, and all ages combined). For the Ratner study [21], data in the age groups "Age 5 to 14" and "Age 15+" were counted in the groups "Age 5 to 19" and "Age 20+", respectively.

For primary vaccinations, and for each complication, the study risk estimates were stratified by age group and by study, and combined across age groups and studies. First, the age-specific risk of each complication was calculated as the number of reported complications divided by the number vaccinated for that age group. Second, the age-specific risk of death from post-vaccinial encephalitis, vaccinia necrosus, and eczema vaccinatum was calculated as the number of deaths from each complication divided by the number vaccinated for that age group. Third, the age-specific case fatality risks from post-vaccinial encephalitis, vaccinia necrosus, and eczema vaccinatum were calculated as the number of deaths from a specific complication divided by the number with that specific complication. For all risk estimates, exact 95% confidence intervals were calculated based on the binomial distribution using R, a freely available open source programming language for statistical computing and graphics [26].

Although contact vaccinia was not the focus of this review, for non-vaccinees with contact-acquired eczema vaccinatum that was reported, we calculated the case fatality risk. For re-vaccinations, the same risk estimates were calculated as for primary vaccinations. However, because the risk of complications was much lower for revaccinations, the risks estimates were stratified by study only and summarized in one table.

Results
Our search yielded a total of 348 studies: 342 from the MEDLINE search, 2 from the reference lists review [27,28], 2 from author communications [29,30], and 2 from our files [27,31]. From this pool, 18 articles of smallpox vaccination complications were identified for further review. Using our selection criteria we excluded 11 studies: 3 did not use the Neff criteria [31–33], 3 did not report complications by vaccination status [34–36], 3 did not report the total number of vaccinations by vaccination status [27,37,38], and 2 studies' results [39,40] were reported in another article [25]. The remaining 7 articles form the basis of this systematic review and represent data from approximately 13,206,095 primary vaccinations and 18,349,359 re-vaccinations [19–25] (Table 1).

The US studies covered the years 1963, 1967, and 1968. Five of the 7 studies were period analyses [19,22–25]. For a period analysis, the number of vaccine complications for a selected geographic location and period of time were ascertained from a variety of sources (Table 1, columns 6 and 7). The at-risk population was the number of persons vaccinated in that location during the same time period. This number was estimated from a variety of sources including population-based regional and national surveys (Table 1, column 8). One study was a prospective cohort study [21] and the other was a clinic-based retrospective cohort study [20].

Primary vaccination
Post-vaccinial encephalitis
The risk of post-vaccinial encephalitis (complication risk, CR), the risk of a post-vaccinial encephalitis death (mortality risk, MR), and the individual risk of dying of post-vaccinial encephalitis (case fatality risk, CFR) by age group are displayed in Table 2. The highest risk for developing post-vaccinial encephalitis was among infants aged <1 year old (risk ratio, 2.80, compared to vaccinees aged 1 year or older). Although the summary risk in this age group was 6.8 cases per million vaccinations, the 1970 Lane et al. study [25] that prospectively surveyed...
physicians estimated a much higher risk (CR, 176.5 cases per million; 95% CI, 36.4–515). The risk in vaccinees aged >1 year was much lower and did not change with age.

The summary case fatality risk for post-vaccinial encephalitis was highest in infants aged <1 year (CFR, 44.4 deaths per 100 cases; 95% CI, 13.7–78.8), however, it was not statistically different from the other age groups ($P$ value = 0.21). For all ages groups, combined there were 11 deaths among 38 cases of post-vaccinial encephalitis (CFR, 28.9 deaths per 100 cases; 95% CI, 15.4–45.9).

**Vaccinia necrosum (progressive vaccinia)**

The risk of vaccinia necrosum, the risk of a vaccinia necrosum death, and the individual risk of dying from vaccinia necrosum were calculated as follows:

### Table 1: Comparison of smallpox vaccination adverse effects studies meeting selection criteria for this systematic review

| Study and year published [Ref] | Source | Number of primary and re-vaccinations | Screening occurred | Complications | Numerator source | Denominator source | Complication | Death |
|-------------------------------|--------|--------------------------------------|-------------------|--------------|-----------------|-------------------|---------------|-------|
| Neff 1967a [19]               | United States, 1963 | 6,239,000 | NR | PVE, VN, EV, GV, AI | Red Cross VIG distribution system, CDC, National Survey of pediatrician and general practitioners | Deaths certificates | Estimated by National Bureau of Census Immunization Survey |
| Neff 1967b [22]               | United States, 1963 (North Carolina, Rhode Island, Washington, Wyoming) | 298,000 | NR | PVE, VN, EV, GV, AI | Retrospective physician survey, Local health officers, Records at major medical centers | Death certificates | Estimated by National Bureau of Census Immunization Survey |
| Lane 1969 [24]                | United States, 1968 | 5,594,000 | NR | PVE, VN, EV, GV, AI | Red Cross VIG distribution system, Red Cross consultants, State & Territorial Epidemiologists, Burroughs-Wellcome Co., Vaccine manufacturers, NCDC Encephalitic Surveillance Unit, NCDC Viral Exanthems Unit | Death certificates | Estimated by National Bureau of Census Immunization Survey |
| Lane 1970 [25]                | United States, 1968 (Alabama, Alaska, Iowa, Kentucky, Maine, Maryland, Rhode Island, South Carolina, Washington, West Virginia) | 596,000 | NR | PVE, VN, EV, GV, AI | Medical and chirurgical faculty, County health officers, Chief pediatricians in general hospitals, Red Cross VIG distribution system, General hospitals, Public health nurses | NR | Estimated by National Bureau of Census Immunization Survey |
| Mellin 1970 [23]              | United States, 1968 (Maryland) | 109,000 | NR | PVE, VN, EV, GV, AI | Medical and chirurgical faculty, County health officers, Chief pediatricians in general hospitals, Red Cross VIG distribution system, General hospitals, Public health nurses | NR | Estimated by National Bureau of Census Immunization Survey |
| Ratner 1970 [21]              | Puerto Rico, 1967 | 269,546 | Yes* | PVE, VN, EV, GV, AI | Medical and chirurgical faculty, University hospital dermatologists, Red Cross VIG distribution system | NR | National smallpox vaccination campaign |
| Neff 1972 [20]                | United States, 1968 (Baltimore pediatric clinic) | 549 | NR | PVE, VN, EV, GV, AI | Pediatric clinic chart review | NR | Clinic chart review |

NR = Not reported, PVE = post-vaccinial encephalitis, VN = vaccinia necrosum, EV = eczema vaccinatum, GV = generalized vaccinia, AI = accidental infection (inadvertent autoinoculation), VIG = Vaccinia immune globulin, NCDC = National Communicable Disease Center. *Vaccinations withheld from persons aged less than 1 year or greater than 60 years, and persons with acute illness, blood dyscrasia, malignancy, pregnancy, eczema or infectious skin disease, eczema in household contacts, steroid therapy, radiation therapy; cerebral damage, or seizure disorder. Wyeth Dryvax product licensed and is used during this period [11]
necrosum by age group are displayed in Table 3. The highest summary risks for developing vaccinia necrosum were among vaccinees aged 20 years or older (CR, 5.3 cases per million; 95% CI, 1.4–13.5). For all ages combined, there were 13 cases of vaccinia necrosum from over 13 million vaccinations (CR, 1.0 cases per million; 95% CI, 0.5–1.7) Almost all cases of vaccinia necrosum occurred in persons with a previously diagnosed hematopoetic malignancy or immunodeficiency condition [24].

For all age groups combined, there were 2 deaths among 13 cases of vaccinia necrosum (CFR, 15.4 deaths per 100 cases; 95% CI, 1.9–45.4).

Eczema vaccinatum
The risk of eczema vaccinatum, the risk of a eczema vaccinatum death, and the individual risk of dying from eczema vaccinatum by age group are displayed in Table 4. For all age groups combined, there were 169 cases of eczema vaccinatum from over 13 million vaccinations.
The summary risks of eczema vaccinatum did not differ across age groups. However, within age groups, the highest risks were recorded from the US studies that used physician surveys to ascertain complications not captured by other reporting mechanisms [22,25]. In these two studies, the risks of eczema vaccinatum ranged from 30.3 to 96.8 cases per million vaccinations, and were higher in infants <1 year, although not statistically significant.

For all age groups combined, there were no deaths among 169 cases of eczema vaccinatum (CFR, 0 deaths per 100 cases; 95% CI, 0.0–2.2). However, among non-vaccinees that developed eczema vaccinatum after contact transmission from a recent vaccinee, 3 of 132 cases died (2.3 deaths per 100 cases; 95% CI, 0.5–6.5) [19,22,24,25].

**Generalized vaccinia**

The risk of generalized vaccinia is displayed in Table 5. The summary risk of developing generalized vaccinia was

---

| Age group and studies | Number vaccinated | V.N. No. | Deaths No. | Risk of complication per million (95% C.I.) | Risk of death per million (95% C.I.) | Case fatality risk per hundred (95% C.I.) |
|-----------------------|------------------|-----------|------------|-------------------------------------------|--------------------------------------|------------------------------------------|
| **Age <1**            |                  |           |            |                                           |                                      |                                          |
| Neff 1967a            | 654,000          | 1         | 0          | 1.5 (0.04, 8.5)                          | 0.0 (0.0, 5.6)                       | 0.0 (0.0, 97.5)                          |
| Neff 1967b            | 31,000           | 0         | 0          | 0.0 (0.0, 122)                           | 0.0 (0.0, 119.0)                     | n/a                                      |
| Lane 1969             | 614,000          | 0         | 0          | 0.0 (0.0, 6.0)                           | 0.0 (0.0, 6.0)                       | n/a                                      |
| Lane 1970             | 17,000           | 0         | 0          | 0.0 (0.0, 217)                           | 0.0 (0.0, 217)                       | n/a                                      |
| Ratner 1970           | 1                | 0         | 0          | n/c                                      | n/c                                  | n/a                                      |
| Neff 1972             | 32               | 0         | 0          | n/c                                      | n/c                                  | n/a                                      |
| **Summary**           | 1,316,033        | 1         | 0          | 0.8 (0.02, 4.2)                          | 0.0 (0.0, 2.8)                       | 0.0 (0.0, 97.5)                          |
| **Age 1 to 4**        |                  |           |            |                                           |                                      |                                          |
| Neff 1967a            | 2,973,000        | 1         | 0          | 0.3 (0.01, 1.9)                          | 0.0 (0.0, 1.2)                       | 0.0 (0.0, 97.5)                          |
| Neff 1967b            | 142,000          | 0         | 0          | 0.0 (0.0, 26.0)                          | 0.0 (0.0, 26.0)                      | n/a                                      |
| Lane 1969             | 2,733,000        | 1         | 0          | 0.4 (0.01, 2.0)                          | 0.0 (0.0, 1.3)                       | 0.0 (0.0, 97.5)                          |
| Lane 1970             | 317,000          | 1         | 0          | 3.2 (0.08, 17.6)                         | 0.0 (0.0, 11.6)                      | 0.0 (0.0, 97.5)                          |
| Ratner 1970           | 68,002           | 0         | 0          | 0.0 (0.0, 54.2)                          | 0.0 (0.0, 54.2)                      | n/a                                      |
| Neff 1972             | 517              | 0         | 0          | 0.0 (0.0, 7110)                         | 0.0 (0.0, 7110)                      | n/a                                      |
| **Summary**           | 6,233,519        | 3         | 0          | 0.5 (0.1, 1.4)                           | 0.0 (0.0, 0.6)                       | 0.0 (0.0, 70.8)                          |
| **Age 5 to 19**       |                  |           |            |                                           |                                      |                                          |
| Neff 1967a            | 2,295,000        | 3         | 0          | 1.3 (0.3, 3.8)                           | 0.0 (0.0, 1.6)                       | 0.0 (0.0, 70.6)                          |
| Neff 1967b            | 110,000          | 0         | 0          | 0.0 (0.0, 33.5)                          | 0.0 (0.0, 33.5)                      | n/a                                      |
| Lane 1969             | 1,959,000        | 2         | 2          | 1.0 (0.1, 3.7)                           | 1.0 (0.1, 3.7)                       | 100 (15.8, 100)                          |
| Lane 1970             | 229,000          | 0         | 0          | 0.0 (0.0, 16.1)                          | 0.0 (0.0, 16.1)                      | n/a                                      |
| Ratner 1970b          | 193,721          | 0         | 0          | 0.0 (0.0, 19.0)                          | 0.0 (0.0, 19.0)                      | n/a                                      |
| **Summary**           | 4,786,721        | 5         | 2          | 1.0 (0.34, 2.44)                        | 0.4 (0.05, 1.5)                      | 40.0 (5.3, 85.3)                         |
| **Age 20 +**          |                  |           |            |                                           |                                      |                                          |
| Neff 1967a            | 317,000          | 2         | 0          | 6.3 (0.8, 22.8)                          | 0.0 (0.0, 11.6)                      | 0.0 (0.0, 84.2)                          |
| Neff 1967b            | 15,000           | 0         | 0          | 0.0 (0.0, 246)                           | 0.0 (0.0, 246)                       | n/a                                      |
| Lane 1969             | 288,000          | 2         | 0          | 6.9 (0.8, 25.1)                          | 0.0 (0.0, 12.8)                      | 0.0 (0.0, 84.2)                          |
| Lane 1970             | 33,000           | 0         | 0          | 0.0 (0.0, 112)                           | 0.0 (0.0, 112)                       | n/a                                      |
| Ratner 1970b          | 107,822          | 0         | 0          | 0.0 (0.0, 34.2)                          | 0.0 (0.0, 34.2)                      | n/a                                      |
| **Summary**           | 760,822          | 4         | 0          | 5.3 (1.4, 13.5)                          | 0.0 (0.0, 4.8)                       | 0.0 (0.0, 60.2)                          |
| **All ages**          |                  |           |            |                                           |                                      |                                          |
| Neff 1967a            | 6,239,000        | 7         | 0          | 1.1 (0.4, 2.3)                           | 0.0 (0.0, 0.6)                       | 0.0 (0.0, 41.1)                          |
| Neff 1967b            | 298,000          | 0         | 0          | 0.0 (0.0, 12.4)                          | 0.0 (0.0, 12.4)                      | n/a                                      |
| Lane 1969             | 5,594,000        | 5         | 2          | 0.9 (0.3, 3.1)                           | 0.4 (0.04, 1.3)                      | 40.0 (5.3, 85.3)                         |
| Lane 1970             | 596,000          | 1         | 0          | 1.7 (0.04, 9.3)                          | 0.0 (0.0, 6.2)                       | 0.0 (0.0, 97.5)                          |
| Mellin 1970           | 109,000          | 0         | 0          | 0.0 (0.0, 33.8)                          | 0.0 (0.0, 33.8)                      | n/a                                      |
| Ratner 1970           | 369,546          | 0         | 0          | 0.0 (0.0, 10.0)                          | 0.0 (0.0, 10.0)                      | n/a                                      |
| Neff 1972             | 549              | 0         | 0          | 0.0 (0.0, 6697)                         | 0.0 (0.0, 6697)                      | n/a                                      |
| **Summary**           | 13,206,095       | 13        | 2          | 1.0 (0.5, 1.7)                           | 0.2 (0.02, 0.5)                      | 15.4 (1.9, 45.4)                         |

n/c = not calculated, n/a = not assessable *Risk and confidence intervals not calculated (n/c) for less than 100 vaccinations. Exact confidence intervals based on the binomial distribution. The Ratner study age groups, "Age 5 to 14" and "Age 15+", were counted in the Table age groups "Age 5 to 19" and "Age 20+", respectively. All ages group includes subjects whose age was unknown.
highest among infants aged <1 year (103.3 cases per million vaccinations; 95% CI, 86.7–122.2). However, within age groups, the highest risks were recorded from the US studies that used physician surveys to ascertain complications not captured by other reporting mechanisms [22,25]. The complication risks ranged from 133.3 to 1647 cases per million vaccinations and were highest in infants aged <1 year. The highest risks were reported from the study that prospectively surveyed physicians [25].

For all age groups combined, there were no deaths among 527 cases of generalized vaccinia (CFR, 0 deaths per 100 cases; 95% CI, 0.0–0.7).

**Accidental infection (inadvertent autoinoculation)**

The risk of accidental infection is displayed in Table 5. For all age groups combined, there were 857 cases of accidental infection from over 13 million vaccinations (CR, 64.9 cases per 1 million vaccinations; 95% CI, 60.6–69.4). The summary risks of accidental infection did not differ across age groups. However, within age groups, the highest risks
were recorded from two US studies: the Lane study [25] that prospectively surveyed physicians and the Neff pediatric clinic study [20]. In the Lane study, the risk ranged from 371.2 to 2118 cases per million vaccinations, and was highest in infants aged <1 year. The Neff study reported 3 accidental infections from 517 vaccinations in the age group 1 to 4 years (CR, 5802.7 cases per million; 95% CI, 1198–16,864).

For all age groups combined, there were no deaths among 857 cases of accidental infection (CFR, 0 deaths per 100 cases; 95% CI, 0.0–0.4).
Re-vaccination

For smallpox vaccine re-vaccinations, the risks of developing specific complications, the risks of a specific complication death, and the individual risks of dying from specific complications by age group are displayed in Table 6. Because the risks were so low compared to primary vaccination, the risks were not stratified by age group. Compared to primary vaccinations, the summary risk of post-vaccinial encephalitis was 26 times lower in re-vaccinations, vaccinia necrosum was 1.5 times lower, eczema vaccinatum was 12 times lower, generalized vaccinia was 29 times lower, and accidental infection was 3.8 times lower. Only 2 deaths occurred from over 19.5 million re-vaccinations (MR, 0.1 deaths per million; 95% CI, 0.0, 0.2).

Table 6: Risk of serious complications (S.C.) and death from smallpox re-vaccinations for ages greater than 1, 1963–1968

| Complication and studies | Number vaccinated (S.C. No.) | Deaths No. | Risk of complication per million (95% C.I.) | Risk of death per million (95% C.I.) | Case fatality risk per hundred (95% C.I.) |
|--------------------------|-----------------------------|------------|--------------------------------------------|-------------------------------------|----------------------------------------|
| Post-vaccinial encephalitis | Neff 1967a 7,775,000 0 0 | 0.0 (0.0, 0.5) | 0.0 (0.0, 0.5) | n/a | n/a |
| Neff 1967b 370,000 0 0 | 0.0 (0.0, 10.0) | 0.0 (0.0, 10.0) | n/a | n/a |
| Lane 1969 8,574,000 0 0 | 0.0 (0.0, 0.4) | 0.0 (0.0, 0.4) | n/a | n/a |
| Lane 1970 998,000 2 0 | 2.0 (0.2, 7.3) | 0.0 (0.0, 3.7) | 0.0 (0.0, 84.2) |
| Mellin 1970 166,000 0 0 | 0.0 (0.0, 22.2) | 0.0 (0.0, 22.2) | n/a | n/a |
| Ratner 1970 465,926 0 0 | 0.0 (0.0, 7.9) | 0.0 (0.0, 7.9) | n/a | n/a |
| Neff 1972 433 0 0 | 0.0 (0.0, 8483) | 0.0 (0.0, 8483) | n/a | n/a |
| Summary 18,349,359 2 0 | 0.1 (0.01, 0.4) | 0.0 (0.0, 0.2) | 0.0 (0.0, 84.2) |
| Vaccinia necrosum | Neff 1967a 7,775,000 2 0 | 0.3 (0.0, 0.9) | 0.0 (0.0, 0.5) | 0.0 (0.0, 84.2) |
| Neff 1967b 370,000 0 0 | 0.0 (0.0, 10.0) | 0.0 (0.0, 10.0) | n/a | n/a |
| Lane 1969 8,574,000 6 2 | 0.7 (0.3, 1.5) | 0.2 (0.03, 0.8) | 33.3 (4.3, 77.7) |
| Lane 1970 998,000 3 0 | 3.0 (0.6, 8.8) | 0.0 (0.0, 3.7) | 0.0 (0.0, 70.8) |
| Mellin 1970 166,000 1 0 | 6.0 (0.2, 33.6) | 0.0 (0.0, 22.2) | 0.0 (0.0, 97.5) |
| Ratner 1970 465,926 0 0 | 0.0 (0.0, 7.9) | 0.0 (0.0, 7.9) | n/a | n/a |
| Neff 1972 433 0 0 | 0.0 (0.0, 8483) | 0.0 (0.0, 8483) | n/a | n/a |
| Summary 18,349,359 12 2 | 0.7 (0.3, 1.1) | 0.1 (0.01, 0.4) | 16.7 (2.1, 48.4) |
| Eczema vaccinatum | Neff 1967a 7,775,000 3 0 | 0.4 (0.1, 1.1) | 0.0 (0.0, 0.5) | 0.0 (0.0, 70.8) |
| Neff 1967b 370,000 5 0 | 13.5 (4.4, 31.5) | 0.0 (0.0, 10.0) | 0.0 (0.0, 52.2) |
| Lane 1969 8,574,000 8 0 | 0.9 (0.4, 1.8) | 0.0 (0.0, 0.4) | 0.0 (0.0, 36.9) |
| Lane 1970 998,000 3 0 | 3.0 (0.6, 8.8) | 0.0 (0.0, 3.7) | 0.0 (0.0, 70.8) |
| Mellin 1970 166,000 1 0 | 6.0 (0.2, 33.6) | 0.0 (0.0, 22.2) | n/a | n/a |
| Ratner 1970 465,926 0 0 | 0.0 (0.0, 7.9) | 0.0 (0.0, 7.9) | n/a | n/a |
| Neff 1972 433 0 0 | 0.0 (0.0, 8483) | 0.0 (0.0, 8483) | n/a | n/a |
| Summary 18,349,359 19 0 | 1.0 (0.6, 1.6) | 0.0 (0.0, 0.2) | 0.0 (0.0, 17.6) |
| Generalized vaccinia | Neff 1967a 7,775,000 3 0 | 0.4 (0.1, 1.1) | n/c | n/c | n/c | n/c |
| Neff 1967b 370,000 1 0 | 2.7 (0.1, 15.1) | n/c | n/c | n/c | n/c | n/c |
| Lane 1969 8,574,000 10 0 | 1.2 (0.6, 2.1) | n/c | n/c | n/c | n/c | n/c |
| Lane 1970 998,000 9 0 | 9.0 (4.1, 17.1) | n/c | n/c | n/c | n/c | n/c |
| Mellin 1970 166,000 1 0 | 6.0 (0.2, 33.6) | n/c | n/c | n/c | n/c | n/c |
| Ratner 1970 465,926 1 0 | 2.1 (0.05, 12.0) | n/c | n/c | n/c | n/c | n/c |
| Neff 1972 433 0 0 | 0.0 (0.0, 8483) | n/a | n/a | n/a | n/a | n/a |
| Summary 18,349,359 25 0 | 1.4 (0.9, 2.0) | n/c | n/c | n/c | n/c | n/c |
| Accidental inoculation | Neff 1967a 7,775,000 8 0 | 1.0 (0.4, 2.0) | n/c | n/c | n/c | n/c | n/c |
| Neff 1967b 370,000 250 0 | 675.7 (594, 765) | n/c | n/c | n/c | n/c | n/c |
| Lane 1969 8,574,000 7 0 | 0.8 (0.3, 1.7) | n/c | n/c | n/c | n/c | n/c |
| Lane 1970 998,000 42 0 | 42.1 (30.3, 56.9) | n/c | n/c | n/c | n/c | n/c |
| Mellin 1970 166,000 3 0 | 18.1 (3.7, 52.8) | n/c | n/c | n/c | n/c | n/c |
| Ratner 1970 465,926 1 0 | 2.1 (0.05, 12.0) | n/c | n/c | n/c | n/c | n/c |
| Neff 1972 433 0 0 | 0.0 (0.0, 8483) | n/a | n/a | n/a | n/a | n/a |
| Summary 18,349,359 311 0 | 16.9 (15.1, 18.9) | n/c | n/c | n/c | n/c | n/c |

n/a = not assessable, n/c = not calculated *Exact confidence intervals based on the binomial distribution.
Discussion

To our knowledge, this is the first systematic review of the severe complications of smallpox vaccination in the USA. In addition to the age-specific complication and mortality risks, the case fatality risks were summarized. Using pooled summary measures, for every million primary vaccinations there were 60 cases of accidental infection, 40 cases generalized vaccinia, 13 cases of eczema vaccinatum, 3 cases of post-vaccinial encephalitis, and 1 case of vaccinia necrosis. However, complications for which vaccinia immune globulin (VIG) was not used (post-vaccinial encephalitis) or not generally required (accidental infection, generalized vaccinia) were significantly under-reported because they were not captured by the VIG distribution program that was used by investigators to ascertain complications. In contrast, the US studies that used direct physician surveys [22,25] reported significantly higher complication risks. For example, the number of complications per million primary vaccinations for all ages combined was 13.4 cases of post-vaccinial encephalitis [25], 263.4 cases of generalized vaccinia [25], and 838.9 cases of accidental infection [22].

The complications with the highest summary case fatality risks were post-vaccinial encephalitis (CFR, 28.9%) and vaccinia necrosum (CFR, 15.4%). There were no recorded deaths among vaccinees from other major complications, including eczema vaccinatum. Deaths from eczema vaccinatum were observed only among non-vaccinees that acquired the disease after contact to a recent vaccinee [38]. Neff et al. reported that contact-acquired eczema vaccinatum resulted in 3 (2.3%) deaths among the 132 cases in the US studies [41]. In contrast, in the United Kingdom (UK) studies contact-acquired eczema vaccinatum resulted in 9 (7.9%) deaths among 89 cases; however, the UK vaccinations occurred in the 1950s using a different vaccinia strain [29,30].

Compared to primary vaccinees, in re-vaccinees the summary risk was 26-fold lower for post-vaccinial encephalitis, 29-fold lower for generalized vaccinia, 12-fold lower for eczema vaccinatum, 3.8-fold lower for accidental infection, and 1.5-fold lower for vaccinia necrosum. Prior vaccination predicted much lower risks for only 3 of the 5 major complications. Therefore, rather than the risks being significantly modified by prior vaccination status, the risk for accidental infection is more likely linked to behavior (autoinoculation) and the risk of vaccinia necrosum is more likely determined by immune status at the time of vaccination. This is consistent with the observation that vaccinia necrosum occurred almost exclusively in vaccinees with an severe cell-mediated immunodeficiency [42].

A strength of this systematic review is that the data were analyzed and summarized by age groups. The complication risks from each study, or combined, can be compared within and across age groups. For example, compared to vaccinees aged 1 year or older, infants aged <1 year had higher summary risks of post-vaccinial encephalitis (risk ratio, 2.80) and generalized vaccinia (risk ratio, 3.14). In contrast, compared to vaccinees aged <20 years, vaccinees aged 20 or older had a higher summary risk of vaccinia necrosum (risk ratio, 7.27).

There are several limitations to this systematic review. First, the studies reviewed were conducted in the 1960s, and routine smallpox vaccination in the United States ended in the early 1970s. Before routine smallpox vaccinations ceased, the characteristics of those persons vaccinated changed as the vaccination risks became better known and potential vaccinees were screened (e.g., infants aged <1 year, history of eczema). To the extent that routine screening for risk factors was occurring, this would have reduced the vaccine complication risks. Only the Ratner prospective cohort study that was conducted in 1967 was able to report vaccination screening criteria [21].

Second, the methods for ascertaining vaccine complications and deaths (i.e., the numerator in the risk estimates) differed between studies. The number of complications ascertained increased as the quantity and quality of ascertainment methods increased. For example, the studies that used direct physician surveys [22,25] recorded more complications that were less severe (generalized vaccinia, accidental infection) or for which VIG was not used (post-vaccinial encephalitis). Therefore, the Lane et al. study [25] that used a prospective physician survey to enhance reporting yielded the highest (and likely the most accurate) vaccine complication risks for that study period. With respect to complications deaths, only 3 studies [19,22,24] reviewed death certificates for this outcome. So it is possible that the other studies underestimated deaths due to vaccine complications.

Third, in the Lane and Neff studies reviewed, the investigators were unable to verify the clinical diagnosis from the reports of adverse events. For example, generalized non-viremic rashes were sometimes misclassified as generalized vaccinia, possibly resulting in an overestimation of the risk of generalized vaccinia [17,18].

Fourth, the methods for estimating the number of primary and repeat vaccinations (i.e., the denominator in risk estimates) differed between studies. Two studies had
data on the actual number of vaccinations given [20,21],
and in the remaining studies the number of vaccinations
were estimated from national or state immunization sur-
vays [19,22,24,25]. Because the complications evaluated
for this review were infrequent, the complication risk esti-
mates are more sensitive to variability in the numerator
than in the denominator. Therefore, inaccuracies in the
estimations of the populations vaccinated would not likely
account for the observed heterogeneity in risk estimates.

Fifth, geographical and temporal factors may have influ-
enced the heterogeneity of risk estimates. Pre-vaccination
screening practices and the diagnosis and treatment of vac-
cine complications, and a change in the distributions of
risk factors (e.g., atopic dermatitis, immunocompro-
minated) among populations that might undergo vaccina-
tion. In spite of all the study limitations, these are the
best available US studies of sufficient size to estimate the
complication and case fatality risks for each major comp-
plication among vaccinees.

This systematic review summarizes the major smallpox
vaccine complication and case fatality risks for predicting
the age-specific burden of vaccine complications in the
event of widespread ring and mass vaccinations. Because
atopic dermatitis and immune compromised states are
more common today than when these studies were con-
ducted [12,43–45], higher vaccine complication rates may
be observed in an outbreak. In comparison, in the current
pre-event smallpox vaccination program, rigorous screen-
ing of almost 500,000 vaccinees has resulted in no cases
of eczema vaccinatum and progressive vaccinia [46,47];
however, very high rates of myopericarditis (about
1:1,700 in civilian vaccinees and 1 per 12,800 in military
vaccinees) and possibly myocardial ischemia have been
observed [48,47,49]. Both potential primary and re-vac-
cinees are at risk for myopericarditis. Similar to post-vac-
cinal encephalitis, there is no screening criteria to reduce
complications rates. For these reasons, and because the
long term effects of myopericarditis are not known, the
ACIP has recommended a "pause" in the USA smallpox
vaccination program until the risks and benefits can be
studied more carefully [50]. Unless there is a smallpox
outbreak, at the current time, the individual risks of pre-
event smallpox vaccination outweigh the potential
benefits.

Competing interests
None declared.

Authors’ contribution
TJA directed the study, co-extracted data, conducted data
entry and statistical analyses, and prepared, revised, and
finalized the manuscript, including revisions. SU con-
dceived and designed the study, screened the articles for
inclusion, and co-extracted data. GWR and SF consulted
on study design, methods, analyses, and manuscript prep-
arnation. All authors extensively contributed to manuscript
editing and revisions. All authors read and approved the
final manuscript.

Acknowledgments
We express our extreme gratitude to Drs. J. Michael Lane and John M. Neff
for reviewing our drafts and providing valuable feedback and direction, and
to Randy Reiter and Wayne Enanoria for assisting in data abstraction for
quality control.

References
1. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling
PB, Hauer J, Layton M, McDade J, Osterholm MT, O’Toole T, Parker
G, Perl T, Russell PK, and Tonat K. Smallpox as a biological
weapon: medical and public health management. Working
Group on Civilian Biodefense. jAMA 1999, 281(22):2127-37.
2. World Health Organization: Declaration of Global Eradication
of Smallpox. Weekly Epidemiological Record 1980, 55:145-152.
3. Schraeder TL and Campion EW: Smallpox vaccination – the call
to arms. New England Journal of Medicine 2001, 344(5):381-2.
4. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK,
Atmar RL, Edelman R, Nolans CM and Belshie RB: Clinical responses
to undiluted and diluted smallpox vaccine. New England Journal
of Medicine 2002, 346(17):1265-74.
5. Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polsch T,
Rothman AL, Kennedy JS, Wolff M, Belshie RB and Ennis FA: Dose-
related effects of smallpox vaccine. New England Journal of
Medicine 2002, 346(17):1275-80.
6. Department of Health and Human Services HHS Press Office: HHS
awards $428 million contract to produce smallpox vaccine:
Acambis/Baxter will produce 155 million doses by end of
2002. 2001
7. Centers for Disease Control and Prevention: Protecting Americans:
Smallpox Vaccination Program. [http://www.bt.cdc.gov/
agent/smallpox/vaccination/vaccination-program-statement.asp],
Accessed March 7, 2003
8. Centers for Disease Control and Prevention: CDC Telebriefing
Transcript: ACIP Smallpox Vaccine Meeting Briefing, Octo-
ber 17, 2002. [http://www.cdc.gov/od/oc/media/mediatranscripts/
t021017.htm], Accessed March 7, 2003
9. Institute of Medicine Committee on Smallpox Vaccination Program
Implementation: Review of the Centers for Disease Control
and Prevention’s Smallpox Vaccination Program Implemen-
tation – Letter Reports 1 to 3. [http://www.nap.edu/catalog/10657.htm][http://
www.nap.edu/catalog/10714.html], Accessed July 1 2003
10. Melzter ML: The Modeling Basis for Vaccination Policy Options. In: Scientific and Policy Considerations in Developing Smallpox Vaccination Options: A Workshop Report. Institute of Medicine (IOM), Board on Health Promotion and Disease Prevention (HPDP), Division of Health Promotion and Disease Prevention (HPDP), 2002:14-17.
11. Centers for Disease Control and Prevention: Vaccinia (Smallpox) Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recommendations and Reports 2001, 50(RR-10).
12. Kemper AR, Davis MM and Freed GL: Expected adverse events in a mass smallpox vaccination campaign. Effective Clinical Practice 2002, 5(2):84-90.
13. Centers for Disease Control and Prevention: Smallpox vaccination and adverse reactions: guidance for clinicians. MMWR 2003, 52.
14. Bartlett J, Borio L, Radonovich L, Mais J, O'Toole T, Mair M, Halsey N, Grow K and Inglesby TV: Smallpox vaccination in 2003: key issues. Clin Infect Dis 2003, 36(7):883-902.
15. Lane JM and Goldstein J: Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med 2003, 138(6):488-93.
16. Centers for Disease Control and Prevention: Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003, 52(7):1-16.
17. Lane JM, Personal communication (mikelane869@yahoo.com). Formerly from the Smallpox Eradication Program, Centers for Disease Control and Prevention, Atlanta, GA.
18. Neff JM: Personal communication (njeff@chmc.org). Center for Children with Special Needs, Children's Hospital and Regional Medical Center, and the Department of Pediatrics, University of Washington School of Medicine, Seattle.
19. Neff JM, Lane JM, Pert JH, Moore R, Millar JD and Henderson DA: Complications of smallpox vaccination. I. National survey in the United States, 1963. New England Journal of Medicine 1967, 276(3):125-32.
20. Neff JM and Drachman RH: Complications of smallpox vaccination, 1968 surveillance in a Comprehensive Care Clinic. Pediatrics 1972, 50(3):481-3.
21. Lane JM: Personal communication (lenco@chmc.org). Formerly from the Smallpox Eradication Program, Centers for Disease Control and Prevention, Atlanta, GA.
22. Neff JM, Lane JM, Pert JH, Moore R, Millar JD and Henderson DA: Complications of smallpox vaccination United States 1963. II. Results obtained by four statewide surveys. Pediatrics 1967, 39(6):916-23.
23. Mellin H, Neff JM, Garber H and Lane JM: Complications of smallpox vaccination, Maryland 1968: Johns Hopkins Medical Journal 1970, 126(3):160-8.
24. Lane JM, Ruben FL, Neff M and Millar JD: Complications of smallpox vaccination, 1968. New England Journal of Medicine 1969, 281(22):1201-8.
25. Lane JM, Ruben FL, Neff M and Millar JD: Complications of smallpox vaccination, clinical 1968: results of ten statewide surveys. Journal of Infectious Diseases 1970, 122(4):303-9.
26. R Development Team: R – A Language and Environment for Statistical Computing and Graphics. [http://www.r-project.org].
27. Clark PS and Lane JM: Complications of smallpox vaccination, 1968. Results of a statewide survey in Alaska. California Medicine 1971, 115(3):7-10.
28. Greenberg M: Complications of vaccination against smallpox. American Journal of Diseases of Children 1948, 76:492-502.
29. Conlybra ET: Illness attributed to smallpox vaccination during 1951–60. Monthly Bulletin of the Ministry of Health and the Public Health Laboratory Service 1964, 23:126-133.
30. Monckton Copeman PW and Wallace HJ: Eczema Vaccinatum. Brit Med J 1964, 2:906-908.
31. Smith JW, Seid LG and Johnson JE 3rd: Smallpox vaccination in hospital personnel. Results of a survey and vaccination program at the Johns Hopkins Hospital. JAMA 1966, 197(5):309-14.
32. Bengtsson E, Hansson S and Nystrom B: Smallpox outbreak and vaccination problems in Stockholm, Sweden 1963. V. Post-vaccinal reactions and complications. Acta Medica Scandinavica. Supplementum 1966, 464:87-104.
33. Schaffner W and Adair R: Smallpox vaccination campaign for Rhode Island hospital personnel. Public Health Reports 1969, 84(5):425-9.
34. Feery BJ: Adverse reactions after smallpox vaccination. Medical Journal of Australia 1977, 2(6):180-3.
35. Haim M, Gdalevich M, Pinzoni M, Ashkenazi I and Shenker J: Adverse reactions to smallpox vaccine: the Israel Defense Force experience, 1991 to 1996. A comparison with previous surveys. Military Medicine 2000, 165(4):287-9.
36. Balasundaram R: Smallpox vaccination: complications and present role. Medical Journal of Malaya 1972, 27(2):89-94.
37. Hallett P: A survey of complications to smallpox vaccination. Medical Journal of Australia 1969, 1(18):898-901.
38. Lane JM, Ruben FL, Abruny E and Millar JD: Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA 1970, 212(3):441-4.
39. Nitzkin JL, Anderson L, Skaggs JW and Hernandez C: Complications of smallpox vaccination in Kentucky in 1968. Results of a statewide survey. Journal of the Kentucky Medical Association 1971, 69(3):184-90.
40. Sinclair MC, Lane JM, Donald WJ and Esco LC: Complications of smallpox vaccination in Alabama, 1968. Southern Medical Journal 1972, 65(1):141-4.
41. Neff JM, Lane JM, Fulginiti VA and Henderson DA: Contact vaccinia – transmission of vaccinia from smallpox vaccination. JAMA 2002, 289(15):1901-5.
42. Bray M and Wright ME: Progressive vaccinia. Clinical Infectious Diseases 2003, 36(6):766-74.
43. Engler RJ, Kenner J and Leung DY: Smallpox vaccination: Risk considerations for patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 2002, 110(3):357-365.
44. Leung DY and Bieber T: Atopic dermatitis. Lancet 2003, 361(9352):151-160.
45. Centers for Disease Control and Prevention: HIV Prevalence Trends in Selected Populations in the United States: Results from National Serosurveillance, 1993–1997. 2001-1:21 [http://www.cdc.gov/hiv/pubs/hivprevalence/toc.htm].
46. Centers for Disease Control and Prevention: Update: Adverse Events Following Civilian Smallpox Vaccination – United States, 2003. MMWR 2003, 52(20):475-77.
47. Grabenstein JD and Winkenwerder Jr W Jr: US Military Smallpox Vaccination Program Experience. JAMA 2003, 289(24):3278-82.
48. Centers for Disease Control and Prevention: Update: Cardiac-Related Events During the Civilian Smallpox Vaccination Program – United States, 2003. MMWR 2003, 52(21):492-496.
49. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, Gray GC, Ostroff S, Eckart RE, Hospenthal DR, Gibson RL, Grabenstein JD, Arness MK and Tornberg DN: Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel. JAMA 2003, 289(24):3281-9.
50. Advisory committee on Immunization Practices. ACIP statement: Advisory committee on Immunization Practices (ACIP) statement on small pox preparedness and vaccination. 2003 [http://www.bt.cdc.gov/agent/smallpox/vaccination/acipjun2003.asp].

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2458/3/26